My guess is not at this time unless something provocative develops. Assuming a medium degree of attractiveness such an opportunity would be by-passed or pushed forward if cardiac - pulmonary acquisition is developed. Obviously, it depends on what, but given what there is in Ovarian and given the company's current positioning in it, probably the former will be emphasized.
This has in it the need to address burgeoning competition from Ventavis. For that matter is CTRX a target? At say, net $130M, it's just a little too much assuming a maximum capital commitment of $100M without squeezing operations. Could CTRX be integrated or merged? Hard to see. Therefore, a more comfortable $50M acquisition makes more sense with some private company.